NF-κB has been found to be activated in human breast cancer cell lines and is considered critical in the genesis of ET resistance in ER+ breast cancer, as it has been shown to promote tamoxifen resistance, early recurrence, metastasis, and worse overall survival [53–56]. Here, NFKB1 is linked to breast carcinoma.